Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.

The Journal of biological chemistry - 19 Sept 2003

Adachi Noritaka, Suzuki Hiromi, Iiizumi Susumu, Koyama Hideki

Abstract excerpt

A number of clinically useful anticancer drugs, including etoposide (VP-16), target DNA topoisomerase (topo) II. These drugs, referred to as topo II poisons, stabilize cleavable complexes, thereby generating DNA double-strand breaks. Bis-2,6-dioxopiperazines such as ICRF-193 also inhibit topo II by inducing a distinct type of DNA damage, termed topo II clamps, which has been believed to be devoid of double-strand...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Chickens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to DNA Topoisomerases, Type II

Share to Etoposide

Share to Genetic Vectors

Share to Piperazines

Share to Transgenes

Source

Identifiers

PMID: 12842886
DOI: 10.1074/jbc.M306500200

Genes

LIG4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.PMID 12842886Read ↗

Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.Semantic proximity Read ↗

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells.Semantic proximity Read ↗

Genetic dissection of vertebrate 53BP1: a major role in non-homologous end joining of DNA double strand breaks.Semantic proximity Read ↗

TDP2–Dependent Non-Homologous End-Joining Protects against Topoisomerase II–Induced DNA Breaks and Genome Instability in Cells and In VivoSemantic proximity Read ↗

Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.Semantic proximity Read ↗

MRN, CtIP, and BRCA1 mediate repair of topoisomerase II–DNA adductsSemantic proximity Read ↗

DNA ligases I and III cooperate in alternative non-homologous end-joining in vertebrates.Semantic proximity Read ↗

Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen PanelSemantic proximity Read ↗

Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damageSemantic proximity Read ↗

Role of TDP2 in the repair of DNA damage induced by the radiomimetic drug BleomycinSemantic proximity Read ↗

Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.Semantic proximity Read ↗

Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.